Bibliographic information
Recommendation
In hospitalized patients with severe or critical COVID-19 and acute hypoxaemic respiratory failure (AHRF) not needing emergent intubation, we suggest high-flow nasal oxygen (HFNO) rather than standard oxygen therapy (SOT)
Recommended in favor
Conditional
Notes and Remarks
The GDG chose not to make a recommendation regarding high-flow nasal oxygen (HFNO) versus continuous positive airway pressure (CPAP) due to uncertainty of the data. Clinicians should therefore choose between the two on the basis of considerations such as availability of devices and the supply of oxygen, their personal comfort and experience, and patient-specific considerations (such as claustrophobia that some patients experience with CPAP masks, and nasal discomfort that some patients experience with HFNO). The GDG elected to extend this recommendation to the paediatric age range (despite the absence of data), given the likely similar direction of benefit, but emphasized the need for more research in this population.
Practical Info There is no specific recommendation for the initial flow rate, FiO2, or titration scheme. Based on clinical experience of the panel, initial flow rates of between 50 and 60 L/min and initial FiO2 of 100% are suggested, titrated to patient SpO2 and work of breathing. In children, a fixed rate of 2 L/min/kg of body weight is suggested. For infection prevention precautions related to the use of these respiratory support devices, please refer to Section 5 on IPC. See also research needs.
Other considerations A specific consideration for HFNO is that these devices may require a higher oxygen flow compared with other non-invasive respiratory support devices. Appropriate calculations of oxygen needs should be made at the facility level when expanding clinical use of HFNO and other non-invasive respiratory devices.
Also Featured In
This recommendation also appears in the following guidelines:
Clinical management of COVID-19: living guideline, 23 June 2022.
Clinical management of COVID-19: living guideline, 15 September 2022.
Clinical management of COVID-19: living guideline, 13 January 2023.
Clinical management of COVID-19: living guideline, June 2025